Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Augmedix (NASDAQ:AUGX) reported its Q4 earnings results on Monday, March 18, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
Augmedix beat estimated earnings by 10.0%, reporting an EPS of $-0.09 versus an estimate of $-0.1.
Revenue was up $3.93 million from the same period last year.
Last quarter the company beat on EPS by $0.02 which was followed by a 13.0% increase in the share price the next day.
Here's a look at Augmedix's past performance:
Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
---|---|---|---|---|
EPS Estimate | -0.12 | -0.13 | -0.15 | -0.15 |
EPS Actual | -0.10 | -0.12 | -0.14 | -0.15 |
Revenue Estimate | 11.42M | 10.41M | 9.36M | 8.51M |
Revenue Actual | 11.77M | 10.78M | 9.63M | 8.75M |
To track all earnings releases for Augmedix visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: AUGX